| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | NEU; HER2; TKR1; CD340; HER-2 |
| Entrez GeneID | 2064 |
| clone | 9B9D8 |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ERBB2 (aa750-987) expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是3条关于ERBB2(HER2)抗体的参考文献及其摘要概括：
---
1. **文献名称**：*Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2*
**作者**：Slamon, D. J., et al.
**摘要**：该研究发表于《New England Journal of Medicine》(2001年)，首次证明抗HER2单克隆抗体曲妥珠单抗(Trastuzumab)联合化疗可显著延长HER2过表达转移性乳腺癌患者的生存期，奠定了靶向HER2治疗的基础。
2. **文献名称**：*Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab*
**作者**：Cho, H. S., et al.
**摘要**：发表于《Nature》(2003年)，通过X射线晶体学解析了HER2胞外结构域及其与曲妥珠单抗(Herceptin)结合的分子机制，揭示了抗体阻断HER2信号传导的结构基础。
3. **文献名称**：*Trastuzumab emtansine for HER2-positive advanced breast cancer*
**作者**：Verma, S., et al.
**摘要**：该临床试验(EMILIA研究)发表于《New England Journal of Medicine》(2012年)，证明抗体药物偶联物T-DM1(曲妥珠单抗-美坦新偶联物)在HER2阳性晚期乳腺癌中优于传统治疗方案，显著延长无进展生存期和总生存期。
---
注：以上为经典文献示例，如需最新研究可补充说明具体方向(如双特异性抗体、耐药机制等)。
ERBB2 (also known as HER2/neu) is a receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR) family. It plays a critical role in regulating cell proliferation, survival, and differentiation. In certain cancers, such as breast and gastric cancers, ERBB2 gene amplification or protein overexpression occurs in ~15-30% of cases, driving uncontrolled cell growth and poor prognosis. This makes ERBB2 a key therapeutic target.
ERBB2-targeted antibodies, like trastuzumab and pertuzumab, bind to specific extracellular domains of the HER2 receptor, blocking downstream signaling pathways (e.g., PI3K/AKT, MAPK) and inducing antibody-dependent cellular cytotoxicity (ADCC). Trastuzumab, the first FDA-approved HER2 antibody (1998), revolutionized treatment for HER2-positive breast cancer, improving survival rates. Pertuzumab, a newer agent, inhibits HER2 dimerization with other EGFR members, enhancing therapeutic efficacy when combined with trastuzumab.
Diagnostically, ERBB2 antibody-based assays (e.g., immunohistochemistry, FISH) are essential for identifying eligible patients. However, resistance mechanisms (e.g., pathway activation, receptor mutations) limit long-term benefits. Current research focuses on combination therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) to overcome resistance.
Overall, ERBB2 antibodies exemplify targeted cancer therapy, bridging molecular diagnostics and precision treatment while inspiring next-generation biologics.
×
